# Abnormal Antioxidant Status in Impaired Glucose Tolerance and Noninsulin-dependent Diabetes Mellitus

S Vijayalingama, A Parthibana, K R Shanmugasundarama, and V Mohanb

\*Department of Biochemistry, P.G. Institute of Basic Medical Sciences, University of Madras, Madras 600-113, India and \*M.V. Diabetes Specialities Centre Madras 600-014, India

A total of 105 subjects with impaired glucose tolerance were classified into two groups, 51 subjects with plasma glucose > 11.1 mmol l<sup>-1</sup> in one of the blood samplings during OGTT, but at 2 h being less than < 11.1 mmol l<sup>-1</sup> were classified as early hyperglycaemics. Fifty-four cases were classified as true IGT, with fasting plasma glucose < 7.8 mmol l<sup>-1</sup> and post plasma glucose level between 7.8 and 11.1 mmol l<sup>-1</sup>. Age and sex matched groups of normals (healthy adults) and NIDDM cases without symptomatic secondary complications were also included in the study. Lipid peroxidation (LPO) product in plasma, erythrocyte, and erythrocyte cell membrane were found to be significantly elevated (p < 0.001) in IGT, early hyperglycaemia and diabetes mellitus while glycosylated haemoglobin was also higher. Antioxidant enzymes superoxide dismutase and catalase were significantly lower in red blood cells obtained from IGT and early hyperglycaemic groups. They were closer to the levels showed in NIDDM confirming that antioxidant deficiency is already present in subjects classified as impaired glucose tolerant. Among the antioxidant scavengers, reduced glutathione (GSH) and ascorbic acid are reduced by 15 % and 20 % in IGT and NIDDM, respectively. We conclude that antioxidant status is poor in both IGT and NIDDM, suggesting an overlap of frank diabetic state in those classified as IGT. It is possible that antioxidant therapy might retard progression from IGT to NIDDM.

KEY WORDS Impaired glucose tolerance Early hyperglycaemia NIDDM Lipid peroxidation Membrane LPO Antioxidant enzymes and scavengers

### Introduction

Impaired glucose tolerance (IGT) is a diagnostic category coined by the National Diabetes Data Group (NDDG)<sup>1</sup> and adopted by the World Health Organization (WHO).<sup>2</sup> Individuals included in this category are those whose tasting plasma glucose (FPG) concentration is less than 7.8 mmol I<sup>-1</sup> and whose 2 h plasma glucose concentration after a 75 g oral glucose tolerance test (OGTT) is between normal and diabetic values (7.8 and 11.1 mmol I<sup>-1</sup>).

IGT as a risk factor for non-insulin-dependent (Type 2) diabetes mellitus (NIDDM) has received much attention.<sup>3</sup> Abdominal obesity, family history of diabetes, glucose and serum insulin levels both fasting and after a glucose load, are all also risk factors for NIDDM.<sup>4</sup>

Reactive oxygen species (ROS) are increasingly formed in diabetes mellitus (DM) by the auto-oxidation of glucose and glycosylated proteins. Baynes postulated a general pathway involving a sequence of events by which oxidative stress leads to tissue damage in diabetes mellitus. According to this, increased formation of ROS and free radicals and their incomplete scavenging lead to peroxidation of cell membrane lipids, inactivation of proteins and fragmentation, crosslinking of DNA and tissue degeneration. Increased lipid peroxidation (LPO) and reduced levels of antioxidants, especially superoxide dismutase (SOD), catalase (CAT), reduced glutathione

(GSH) and ascorbic acid (vitamin C), are reported in NIDDM.<sup>7</sup>

The investigation presented here is on the assessment of antioxidant status and lipid peroxidation, in subjects with IGT. This is compared with healthy subjects and with patients with established NIDDM.

#### Patients and Methods

The following five groups of subjects were studied:

- IGT was diagnosed according to the WHO criteria, i.e. fasting plasma glucose < 7.8 mmol l<sup>-1</sup> and 2 h glucose (after 75 g oral glucose load) between 7.8 and 11.1 mmol l<sup>-1</sup>. Among the 113 subjects who fell into this category, 54 showed plasma glucose concentrations < 11.1 mmol l<sup>-1</sup> in the blood sampling at 30, 60, and 90 min also. They are classed as true IGT.
- Fifty-one IGT subjects had fasting plasma glucose < 7.8 mmol l<sup>-1</sup>, while one of the 3 samples (30, 60 or 90 min after glucose load) was above 11.1 mmol l<sup>-1</sup>, although at 2 h plasma glucose had dropped below 11.1 mmol l<sup>-1</sup>. This group is classified as early hyperglycaemia.
- 3. Seventeen subjects showed fasting plasma glucose < 7.8 mmol l<sup>-1</sup> and 2 h post glucose, plasma level

### ORIGINAL ARTICLES



> 11.1 mmol l<sup>-1</sup>. Their HbA<sub>1C</sub> was in the range of 5.2 to 8.4 %. Eight out of the 17 cases had NIDDM diagnosed at the time of the study. This group of 17 are classified as early DM.

- Sixty-seven cases of NIDDM without any secondary complications attending the M.V. Diabetes Specialities Centre, Madras-14 were studied. Their blood glucose at fasting and 2 h post glucose load were > 7.8 and 11.1 mmol l<sup>-1</sup>.
- Ninety subjects with normal pattern during oral glucose tolerance test (OGTT) (with 75 g glucose load) were included as healthy controls. They had come to the centre for diabetes check up, either because of family history or as a precautionary meas-

All subjects were also screened for other complications by routine clinical examination including chest X-ray, ECG, Doppler examination for peripheral vessel disease, X-rays to detect pancreatic calculi, ophthalmic examination and laboratory tests including blood haemoglobin, plasma albumin, serum transaminases, and microalbuminuria. A detailed case history which included physical measurements, duration, and family history of diabetes and food habits was obtained from each individual.

OGTT was performed with 75 g glucose load, and blood glucose assay at 0, 30, 60, 90, and 120 min by the glucose oxidase method (Corning Plus Autoanalyser). An aliquot of fasting blood sample was collected with EDTA (1 mg ml<sup>-1</sup>) as anticoagulant. Glycosylated haemoglobin (HbA<sub>1C</sub>) was measured according to Wang and Yang<sup>8</sup> in the haemolysate. The erythrocyte membrane was isolated according to the method of Dodge *et al.*<sup>9</sup> and modified by Shanmugasundaram *et al.*<sup>10</sup> Lipid peroxidation was assayed as thiobarbituric acid reactive species (TBARS) and expressed in terms of malondial-dehyde (MDA) according to the method of Yagi *et al.*<sup>11</sup> in the plasma and by the method of Cynamon *et al.*<sup>12</sup> in the erythrocyte and erythrocyte membrane.

The enzymatic and non-enzymatic antioxidants were also assayed. Glutathione peroxidase (GPx) and superoxide dismutase (SOD) were assayed in the haemolysate by the methods of Rotruck *et al.*<sup>11</sup> and Misra and Fridovich,<sup>11</sup> respectively. Membrane bound catalase was assayed according to Sinha.<sup>15</sup> Vitamin A<sup>16</sup> and vitamin E<sup>17</sup> were estimated in the plasma, while vitamin C<sup>18</sup> and reduced glutathione<sup>19</sup> were estimated in the whole blood.

#### Statistical Analysis

Statistically significant differences between the values of IGT, early hyperglycaemia, and NIDDM when compared to controls were obtained using Students *t*-test. The values are expressed as mean ±SD for the five different groups separately.

Quality control of laboratory analysis was maintained over the period studied and technical error was arrived

at by the following formula and as described by earlier workers<sup>2n</sup> using 25 samples for each test.

$$\sqrt{\frac{\Sigma d^2}{2N}} \times \frac{100}{\text{Total sample mean}}$$

where d = difference between duplicate values for the same sample

N = number of samples analysed.

The technical error was found to be 1.6 % SOD, 1.06 % CAT, 0.81 % GPx, 0.2 % GSH, 1.2 % vitamin A, 1.3 % vitamin E, 1.0 % vitamin C, 0.55 % plasma LPO, 1.04 % erythrocyte LPO, and 0.85 % erythrocyte membrane LPO.

#### Results

Table 1 shows the clinical and anthropometric characteristics of the study group classified according to the glucose tolerance status. Around 80 % of the diabetic population and the IGT and early hyperglycaemia subjects had a positive family history of diabetes. The mean value of body mass index (BMI) in subjects with diabetes was comparable to the control population.  $HbA_{1C}$  (6.2  $\pm$  1.1 %) was significantly higher in those classified as early hyperglycaemia.

Lipid peroxidation in plasma, erythrocytes, and erythrocyte membrane is shown in Table 2. A statistically significant increase in lipid peroxidation was seen both in IGT and in early hyperglycaemia when compared to the healthy controls.

From Table 3, it can be seen that the antioxidant defences are weak in IGT. The antioxidant scavengers vitamins E and C and reduced glutathione (GSH) were significantly lower in IGT when compared to healthy controls. SOD and CAT are also markedly lowered. The antiperoxidative enzyme GPx was significantly higher (nearly 50 %) in those with impaired glucose tolerance, early hyperglycaemia, and NIDDM, when compared to the healthy controls.

#### Discussion

While the criteria for classifying IGT has two parameters, namely the fasting plasma glucose level of < 7.8 mmol l <sup>-1</sup> and a 2 h glucose level between 7.8 and 11.1 mmol l<sup>-1</sup>, a significant number of subjects have their plasma glucose rise above 11.1 mmol l<sup>-1</sup> during the early phase of the OGTT (i.e. within 90 min) and their hyperglycaemic condition is acknowledged in our classification into early hyperglycaemia. Both IGT and early hyperglycaemia groups show statistically significant rise in HbA<sub>1C</sub>, suggesting that with the present criteria for IGT classification, subjects with diabetic pathological changes may also be labelled as having IGT, and hypoglycaemic therapy delayed or denied to them at the early stages. In other centres also<sup>21</sup> subjects with IGT had higher than normal levels of glycated haemoglobin as in our study.



# **ORIGINAL ARTICLES**

Lible 1. General data of the population studied

Subjects	Healthy	Impaired glu	icose tolerance	Early DM (n = 17)	NIDDM without complications (n = 67)
	controls (n = 90)	IGT (n = 54)	Early hyperglycaemia (n = 51)		
Duration of DM (range)	-	-	-	0-8 months	7 months-5 years)
Age (yr)	47 ± 6	45 ± 9	$44 \pm 10$	45 ± 8	44 ± 9
Males (%)	68	62	61	60	75
Lamily history of DMb	30	80	76	92	. 83
81/1 (kg m <sup>-2</sup> )	24 ± 5.0	$26 \pm 4.0$	$26 \pm 3.0$	$25 \pm 2.0$	$23 \pm 8.0$
Fasting blood glucose	$4.9 \pm 0.5$	$5.49 \pm 0.5^{*}$	$6.47 \pm 3.3^{a}$	$8.45 \pm 2.7^{a}$	9.5 ± 3.7°
110A1C (%)	$4.9 \pm 0.5$	6.2 ± 1.1*	$6.8 \pm 1.0^{\circ}$	8.6 ± 2.0 <sup>a</sup>	11.2 ± 1.5 <sup>a</sup>

Table 2. Lipid peroxidation in terms of MDA in the plasma, erythrocytes, and erythrocyte membrane in diabetes mellitus, impaired slucose tolerance, and healthy controls

Parameters	Healthy controls $(n = 90)$	Impaired glucose tolerance		Early DM $(n=17)$	NIDDM without complications
		IGT (n = 54)	Early hyperglycaemia (n = 51)	(n = 17)	(n = 67)
Plasma MDA (nmol dl-1)	190 ± 20	201 ± 40°	223 ± 48ª	280 ± 25ª	311 ± 45*
Erythrocyte MDA (nmol MDA 10 <sup>-12</sup> cells)	$13.0 \pm 1.5$	17.7 ± 5.8*	20.1 ± 5.9 <sup>a</sup>	27.0 ± 5.0°	$35.2 \pm 2.0^{\circ}$
Erythrocyte membrane MDA (nmol MDA 10 <sup>-12</sup> cells)	261 ± 44	317 ± 102*	443 ± 117*	490 ± 104*	673 ± 119*

statistically significant alterations from controls is expressed as \* p < 0.001.

Table 3. Antiperoxidative enzyme status and antioxidant scavengers in diabetes mellitus, impaired glucose tolerance and realthy controls.

Parameters	Healthy	Impaired glucose tolerance		Early DM	NIDDM without
	controls (n = 90)	(n = 54) hypers	Early hyperglycaemia (n = 51).	(n = 17)	complications (n = 67)
Glutathione peroxidase (μg GSH liberated/min/mg Hb)	5.9 ± 0.6	7.2 ± 1.2*	7.3 ± 1.1*	7.2 ± 0.3°	7.2 ± 0.3 <sup>a</sup>
Superoxide dismutase (IU mg Hb <sup>-1</sup> )	$3.4 \pm 0.4$	$2.9 \pm 0.4^{\circ}$	$2.6 \pm 0.3^{a}$	2.5 ± 0.4*	2.6 ± 0.3*
Catalase (µmol H <sub>2</sub> O <sub>2</sub> consumed/min/ 10 <sup>12</sup> cells)	$4.4 \pm 0.5$	4.1 ± 0.7*	$3.9 \pm 0.8^{a}$	3.9 ± 0.6*	3.8 ± 0.6 <sup>a</sup>
Vitamin A (µmol I <sup>-1</sup> )	2.21 ± 0.19	2.19 ± 0.13	2.14 ± 0.19	2.13 ± 0.17	$2.18 \pm 0.16$
Vitamin E (µmol I <sup>-1</sup> )	25.1 ± 1.6	22.4 ± 2.3*	21.9 ± 1.9*	21.4 ± 2.1°	$20.0 \pm 2.3^{-2}$
Vitamin C (µmol I-1)	60.9 ± 7.3	48.8 ± 12.7*	47.6 ± 12.1°	$44.7 \pm 8.0^{\circ}$	44.3 ± 5.5°
GSH (µmol l <sup>-1</sup> )	53.4 ± 6.0	45.3 ± 7.1*	45.0 ± 6.2°	45.1 ± 4.5°	45.6 ± 6.5°

statistically significant alterations from controls is expressed as  $^{\bullet}p < 0.001$ .

<sup>(</sup>i,T: fasting blood glucose < 7.8 mmol l  $^{\rm I}$ , postprandial 7.8–11.1 mmol l $^{\rm I}$ . tarly hyperglycaemia: fasting blood glucose < 7.8 mmol l $^{\rm I}$ , post prandial > 11.1 mmol l $^{\rm I}$  statistically significant alterations from controls is expressed as \*p < 0.001. \*At least one parent with DM.




Figure 1. Interrelationship between antioxidant scavengers according to Niki (1987)

Kadowaki<sup>22</sup> observed that the initial degree of hyperglycaemia is an important index predictive of subsequent worsening to diabetes. Marshall *et al.*<sup>23</sup> observed that subjects with IGT have an increased risk of developing NIDDM.

We found that the lipid peroxidation products in the plasma, erythrocyte, and cell membrane were significantly elevated in IGT. Lipid peroxidation was 10 % higher in plasma and 20 % higher in red cell membrane obtained from IGT subjects when compared to healthy controls.

The elevated levels of lipid peroxidation in plasma, cells, and cell membrane in our subjects with IGT and NIDDM were accompanied by diminished antioxidants and this increased with increasing glucose intolerance, in that the abnormalities were greater in those with frank diabetes than in those in early hyperglycaemia and impaired glucose tolerance. In contrast to the effect of glucose intolerance on the antioxidant enzymes SOD and catalase, we found that the peroxide inactivating enzyme glutathione peroxidase (GPx) was raised in IGT, early hyperglycaemia and also in symptomatic NIDDM. However, GPx requires glutathione in its reduced form (GSH) as a cofactor to enable it to inactivate peroxide and function as an effective antioxidant. Our data show significantly lower levels of GSH in IGT, early hyperglycaemia, and NIDDM. Thus, the effective peroxide detoxification in the cell appears to be impaired and this may contribute to antioxidant deficiency.

Normally the body has an abundant supply of 'antioxidants' that delay or inhibit oxidation and neutralize the reactive oxygen species. Glutathione is endogenously synthesized predominantly in the liver<sup>24</sup> and in other tissue cells. It is the first line of defence against prooxidant stress.<sup>25</sup> It exists in the oxidised (GSSG) and reduced (GSH) forms which are interconvertible. GSH in turn keeps up the reduced forms of vitamins C and E, which participate in neutralizing the free radicals as and when they are formed.<sup>26</sup> (Figure 1). Thus, GSH is able to spare vitamins C and E in the cell in combating free radicals at the cytoplasmic and membrane level, respectively.

In IGT the antioxidant scavengers are already low, and this may account for the higher lipid peroxidation

products seen. The observation presented is the first demonstration that in IGT altered antioxidant status is already developed and may contribute to tissue damage resulting in progression to NIDDM. The subjects with IGT are already-presenting symptoms of metabolic derangements due to hyperglycaemia like elevated HbA<sub>1C</sub>, increased lipid peroxidation, and mild antioxidant depletion. A rethinking on the criteria for NIDDM may not be inappropriate. It would be interesting to study the effect of antioxidant therapy in subjects with IGT, and follow-up their glucose tolerance in the next couple of years to check whether antioxidant therapy could check the development of symptomatic diabetes mellitus.

#### Acknowledgements

We express our gratitude to R Mohan of M.V. Diabetes Specialities Centre, Madras, India for providing the required blood samples and the clinical picture, and to R.D. Birla Smarak Kosh for financial aid provided to A. Parthiban during the period of the study.

#### References

- National Diabetes Data Group. Classification and diagnosis of diabetes and other categories of glucose intolerance. Diabetes 1979; 29: 1039–1057.
- WHO Expert Committee on Diabetes Mellitus. Diabetes Mellitus. Second Report. Technical Report Series 646. Geneva: World Health Organization, 1980.
- Jarrett RJ, Keen H, Fuller JH, McCartney M. Worsening to diabetes in men with impaired glucose tolerance ('borderline diabetes'). Diabetologia 1979; 16: 25–30.
- Ohlson LO, Larsson B, Erikson H, Svardsudd K, Welin L, Tibblin G. Diabetes mellitus in Swedish middle-aged men: the study of men born in 1913 and 1923. *Diabetolo-gia* 1987; 30: 386–393.
- Jones AF, Jennings PE, Winkles J, Lunec J, Barnett AH. Impaired serum antioxidant activity in diabetic microangiopathy. *Diabetic Med* 1985; 2: 502.
- Baynes JW. Perspectives in diabetes. Role of oxidative stress in development of complication in diabetes. *Diabetes* 1991; 40: 405–412.
- Loven DP, Oberley LW. Free radicals, insulin action and diabetes. In: Oberley LW, eds. Superoxide Dismutase Vol. 3. Boca Raton, Florida: CRC Press, 1985; 151–189.

## **ORIGINAL ARTICLES**

- 8 Wang J, Yang G. Colorimetric detection of glycosylated haemoglobin in Human. Yixylyna Xuebao 1982; 7: 325-328.
- Dodge JT, Carolyn M, Donald JH. Preparation and chemical characteristics of haemoglobin free ghosts of human erythrocytes. Arch Biochem Biophys 1963; 100: 199-230.
- Shanmugasundaram KR, Padmavathi C, Acharya S, Vidhyalakshmi N, Vijayan VK. Exercise induced cholesterol depletion in human red cell membranes. Exp Physiol 1992; 77: 933–936.
- Yagi K. Simple fluorimetric assay for lipid peroxides in blood plasma. Biochem Med 1976; 15: 212–215.
- Cyanomon AA, Isenberg JN, Nguyen WH. Erythrocyte malondialdehyde release in vitro: a functional measure of vitamin A status. Clin Chim Acta 1985; 151: 169–176.
- Rotruck JT, Pope AC, Ganther HE, Swanson AB, Hafeman DG, Hoekstra MG. Selenium: biochemical role as a component of glutathione peroxidase purification and assay. Science 1973; 179: 588-590.
- Misra HP, Fridovich I. The role of superoxide anion in the auto-oxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 1972; 247: 3170–3175.
- Sinha AK. Colorimetric assay of catalase. Anal Biochem 1972; 47: 389–395.
- Bayfield RF, Cole ER. Colorimetric estimation of vitamin A with trichloroacetic acid. In: McCormick DB, Wought LD, eds. Methods in Enzymology. New York: Academic Press, 1980: 189–195.
- Emmerie A, Engle C. Colorimetric determination of α-tocopherol. (vitamin E). Rec Tran Chin 1938: 57: 1351–1355.

- Omaye ST, Turnabull JD, Sauberlich HE. Selected methods for the determination of ascorbic acid in animal cells, tissues and fluids. Methods in Enzymology. New York: Academic Press, 1979: 1–11.
- Beutler E, Kelley BM. The effect of sodium nitrate on red cell glutathione. Experentia 1963; 19: 96–97.
- Thomas I, Gupta S, Sempos C, Cooper R. Serum lipids of Indian physicians living in the US compared to the US born physicians. Atherosclerosis 1986; 61: 99–106.
- Hall PM, Cook JG, Sheldon J, Rutherford SM, Gould RJ. Glycosylated haemoglobin and glycosylated plasma proteins in the diagnosis of diabetes mellitus and impaired glucose tolerance. *Diabetes Care* 1984; 7: 147–150.
- Kadowaki T, Miyale Y, Hagura R, Akanuma Y, Kajinuma H, Kuzuya N, et al. Risk factors for worsening to diabetes subjects with impaired glucose tolerance. *Diabetologia* 1984; 26: 44–49.
- Marshall JA, Hoag S, Shetterly S, Hamman RF. Dietary fat predicts conversion from impaired glucose tolerance to NIDDM. *Diabetes Care* 1994; 16: 50–55.
- Lauterberg BH, Smith CV, Mitchell JR. Regulation of hepatic glutathione homeostasis. In: Mitchell JR, Horning MG, eds. *Drug Metabolism and Drug Toxicity*. New York: Raven Press, 1984: 321–330.
- Nicotera P, Orrenius S. Role of thiols in protection against biological reactive intermediates. Adv Exp Med Biol 1986; 187: 41–51.
- Niki E. Interaction of ascorbate and α-tocopherol. Ann NY Acad Sci 1987; 498: 186–199.